News

Matthew I. Milowsky, MD, discusses advances with checkpoint inhibitors in the treatment paradigm for urothelial cancer.

Researchers at Vanderbilt University and the University of Leeds in England have successfully performed autonomous retroflexion of a robotic capsule during colonoscopy in a subject animal.

Wolfgang Janni, MD, PhD, discusses toxicity management with neratinib and other agents for HER2-positive breast cancer, as well as emerging treatments and impactful trials in the field.

Steven Coutre, MD, discusses ongoing efforts to enhance frontline outcomes for patients with CLL.

The safety and tolerability of chimeric antigen receptor T-cell therapy is being explored in an ongoing single-arm, phase I clinical trial for patients with advanced non–small cell lung cancer.

Daniel Morgensztern, MD, discusses both the single-agent and combination immunotherapy data in NSCLC and what researchers are poised to do next in the field.

Adding bevacizumab to standard platinum-based chemotherapy demonstrated a clinically significant improvement in median overall survival in women with recurrent ovarian cancer.

Median overall survival was not improved with zoptarelin doxorubicin, a hybrid molecule combining an LHRH-agonist and doxorubicin, in a phase III advanced endometrial cancer trial.

Pembrolizumab has been approved by the European Commission for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma.

Ann Marie Beddoe, MD, discusses a study implementing cervical cancer screening and highlights HPV predictors in developing countries.

Women who underwent bariatric surgery to combat obesity were less likely to develop any cancer and also less likely to develop female-specific cancers, acording to study results published in <em>Gynecologic Oncology.</em>

The combination of the investigational agent birinapant and carboplatin could eliminate platinum-resistant, high-grade serous carcinoma (HGSC) ovarian tumor cells, according to preclinical findings published in&nbsp;<em>Precision Oncology.</em>

With a vote of 217 to 213, House Republicans have passed a revised version of the American Health Care Act (AHCA), without any Democratic support, and despite strenuous opposition from the healthcare community.

Richard M. Stone, MD,&nbsp;discusses the impact that midostaurin could have for patients with AML, as well as ongoing research with the agent.

Aarti Bhatia, MD, discusses newer single agents and combination treatments being investigated for patients with head and neck cancer.

David M. Sabatini, MD, PhD, has been declared the winner of the 2017 Lurie Prize in Biomedical Sciences from the Foundation for the National Institutes of Health.

Memorial Sloan Kettering Cancer Center has named Luis A. Diaz, MD, as the head of the Division of Solid Tumor Oncology. He will be taking over the role as the former head of the department, David R. Spriggs, MD, steps down following nearly 13 years of service.

Benjamin L. Judson, MD, highlights the importance of a multidisciplinary team and shares insight on some of the advancements related to surgery for patients with head and neck cancer.

Siddhartha Devarakonda, MD, highlights&nbsp;the importance of testing for molecular markers, some of the rarer mutations, and what work lies ahead for the field of NSCLC.

Debu Tripathy, MD, discusses&nbsp;current and emerging treatment strategies in the neoadjuvant setting for patients with HER2-postive breast cancer.

Lynn Acton, MS, CCC (SLP) discusses&nbsp;the significance of swallowing modalities for patients with head and neck cancer during and after radiation therapy.

NYU Langone&rsquo;s Perlmutter Cancer Center has announced that Ophira Ginsburg, MD, will be director of its new High-Risk Program, which will identify, study, and care for patients with hereditary syndromes that increase their risk for developing cancer.

Nivolumab (Opdivo) demonstrated promise as a second-line therapy for patients with hepatocellular carcinoma (HCC), according to results of the CheckMate-040 trial presented at the 2017 International Liver Congress.

Stereotactic body radiotherapy is safe and effective in patients &ge;80 years with early-stage non&ndash;small cell lung cancer, results of a multi-center retrospective analysis showed.

NYU Langone&rsquo;s Perlmutter Cancer Center (PCC) has announced that Ahmad Samer Al-Homsi, MD, MBA, will lead a new bone marrow transplantation program at the center for treating blood-borne cancers, including leukemia, lymphoma, and multiple myeloma.

Dax Kurbegov, MD, was named vice president and physician-in-chief of clinical programs at Sarah Cannon in Nashville, Tennessee. He will oversee the expansion of Sarah Cannon&rsquo;s cancer network, which sees more than 120,000 newly diagnosed cancer cases per year.

Jonathan Riess, MD, discusses the game-changing efficacy of osimertinib in NSCLC and its potential in combination, considering factors for choosing an EGFR TKI, and the burgeoning questions clinicians still have with the<em> EGFR</em>-mutant population.

Bradley J. Monk, MD, discusses&nbsp;his insight on the potential of immunotherapy in ovarian cancer, as well as what promise it might hold in other gynecologic malignancies.

An overview of FDA news that happened in April.

The PD-L1 inhibitor durvalumab has been granted an accelerated approval by the FDA for the treatment of patients with locally advanced or metastatic urothelial carcinoma.